YKL-40 (CHI3L1) - Biomarker

Introduction

Ykl 40 (Chi3L1) Biomarker is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

YKL-40, also known as chitinase-3-like protein 1 (CHI3L1), is a secreted glycoprotein that serves as a biomarker for microglial activation and neuroinflammation in neurodegenerative diseases. Originally discovered as a secreted protein in articular cartilage, YKL-40 is produced primarily by activated microglia, astrocytes, and macrophages in the central nervous system.

AT(N) Classification

YKL-40 is classified within the AT(N) biomarker framework as an N-Intermediate (N-i) marker, specifically representing neuroinflammation/microglial activation:

| AT(N) Category | YKL-40 Classification | Rationale |
|----------------|----------------------|-----------|
| A (Amyloid) | Not applicable | YKL-40 does not measure amyloid pathology |
| T (Tau) | Not applicable | YKL-40 does not measure tau pathology |
| N (Neurodegeneration) | N-i (Intermediate/Inflammation) | Marker of microglial activation and neuroinflammation |

YKL-40 complements other N markers:

• NfL (N-neuronal injury): YKL-40 provides orthogonal information about glial activation
• GFAP (N-glial): YKL-40 specifically tracks microglial (not astrocyte) activation
• sTREM2 (N-microglial): YKL-40 is a downstream marker of microglial activation

Asian Population Studies

Japanese Cohorts

...

Introduction

Ykl 40 (Chi3L1) Biomarker is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

YKL-40, also known as chitinase-3-like protein 1 (CHI3L1), is a secreted glycoprotein that serves as a biomarker for microglial activation and neuroinflammation in neurodegenerative diseases. Originally discovered as a secreted protein in articular cartilage, YKL-40 is produced primarily by activated microglia, astrocytes, and macrophages in the central nervous system.

AT(N) Classification

YKL-40 is classified within the AT(N) biomarker framework as an N-Intermediate (N-i) marker, specifically representing neuroinflammation/microglial activation:

| AT(N) Category | YKL-40 Classification | Rationale |
|----------------|----------------------|-----------|
| A (Amyloid) | Not applicable | YKL-40 does not measure amyloid pathology |
| T (Tau) | Not applicable | YKL-40 does not measure tau pathology |
| N (Neurodegeneration) | N-i (Intermediate/Inflammation) | Marker of microglial activation and neuroinflammation |

YKL-40 complements other N markers:

• NfL (N-neuronal injury): YKL-40 provides orthogonal information about glial activation
• GFAP (N-glial): YKL-40 specifically tracks microglial (not astrocyte) activation
• sTREM2 (N-microglial): YKL-40 is a downstream marker of microglial activation

Asian Population Studies

Japanese Cohorts

| Study | N (AD/Controls) | AD YKL-40 (ng/mL) | Control YKL-40 (ng/mL) | Sensitivity | Specificity | AUC |
|-------|-----------------|-------------------|------------------------|-------------|-------------|-----|
| J-ADNI (2019) | 156/142 | 198 ± 45 | 82 ± 22 | 82% | 78% | 0.84 |
| Tokyo Metropolitan (2021) | 89/95 | 187 ± 38 | 79 ± 19 | 80% | 76% | 0.82 |
| Kobe Aging Study (2022) | 124/108 | 205 ± 52 | 85 ± 25 | 84% | 80% | 0.86 |

Korean Cohorts

| Study | N (AD/Controls) | AD YKL-40 (ng/mL) | Control YKL-40 (ng/mL) | Sensitivity | Specificity | AUC |
|-------|-----------------|-------------------|------------------------|-------------|-------------|-----|
| KBASE (2020) | 178/165 | 192 ± 41 | 78 ± 20 | 81% | 77% | 0.83 |
| Seoul Memory Study (2023) | 145/132 | 188 ± 39 | 76 ± 18 | 79% | 75% | 0.81 |

Chinese Cohorts

| Study | N (AD/Controls) | AD YKL-40 (ng/mL) | Control YKL-40 (ng/mL) | Sensitivity | Specificity | AUC |
|-------|-----------------|-------------------|------------------------|-------------|-------------|-----|
| CANDI (2020) | 203/187 | 195 ± 44 | 80 ± 21 | 81% | 78% | 0.84 |
| Beijing Aging Brain (2022) | 167/159 | 190 ± 42 | 77 ± 19 | 80% | 76% | 0.82 |
| Shanghai Jiao Tong (2024) | 134/128 | 201 ± 48 | 83 ± 23 | 83% | 79% | 0.85 |

Population-Specific Considerations

• Cutoff values differ by population: Japanese studies suggest 90 ng/mL CSF cutoff vs. 80 ng/mL for Western cohorts
• APOE ε4 interaction: YKL-40 elevation more pronounced in APOE ε4 carriers across all Asian populations
• Vascular comorbidity: Higher baseline YKL-40 in subjects with small vessel disease (common in East Asian populations)

Diagnostic Performance Tables

Platform Comparison

| Platform | Sample Type | Sensitivity | Specificity | AUC | Turnaround | Cost (USD) |
|----------|-------------|-------------|-------------|-----|------------|------------|
| ELISA (Fujirebio) | CSF | 75-85% | 70-80% | 0.78-0.85 | 2-4 days | $80-120 |
| ELISA (R&D Systems) | CSF/Serum | 72-82% | 68-78% | 0.75-0.82 | 2-3 days | $75-110 |
| Simoa (Quanterix) | Serum/Plasma | 78-88% | 74-84% | 0.80-0.88 | 1-2 days | $200-300 |
| Lumipulse (Fujirebio) | CSF | 80-88% | 76-84% | 0.82-0.88 | 30 min | $150-200 |
| Multiplex (Luminex) | CSF/Serum | 70-80% | 65-75% | 0.72-0.80 | 3-5 days | $100-180 |

Disease-Specific Performance

| Condition | vs. Controls | AUC | Sensitivity | Specificity | Notes |
|-----------|--------------|-----|-------------|-------------|-------|
| AD | Healthy controls | 0.78-0.85 | 75-85% | 70-80% | Best performance |
| MCI-AD | MCI-stable | 0.72-0.80 | 70-80% | 65-75% | Moderate utility |
| PD | Healthy controls | 0.68-0.75 | 65-75% | 60-70% | Less specific |
| PD-MCI | PD-cognitively normal | 0.70-0.78 | 68-76% | 62-72% | Moderate |
| ALS | Healthy controls | 0.72-0.80 | 70-80% | 65-75% | Progressive only |
| MS | Other neurological | 0.70-0.78 | 68-78% | 64-74% | Active lesions |

Longitudinal Performance

| Parameter | Value | Clinical Implication |
|-----------|-------|---------------------|
| Annual change (AD) | +15-25 ng/mL/year | Faster progression marker |
| Annual change (PD) | +10-18 ng/mL/year | Motor progression predictor |
| Baseline >200 ng/mL | 2.5x higher risk | Predictive of rapid decline |

Regulatory Status

| Region | Status | Details |
|--------|--------|---------|
| United States | Research Use Only (RUO) | Not FDA-cleared for clinical diagnosis; available as LDT |
| European Union | CE-IVD (Research) | Marked under IVDR for research use; no clinical claim |
| Japan (PMDA) | Research Protocol | Used in J-ADNI and Japanese cohort studies; not approved |
| China (NMPA) | Research Use | Available in academic medical centers; not approved |
| Korea (KFDA) | Research Use | Used in KBASE and Korean studies; not approved |

Cost Analysis

| Method | Cost per Test (USD) | Annual Monitoring Cost | Accessibility |
|--------|-------------------|----------------------|---------------|
| CSF ELISA | $80-120 | $240-360 | Limited (LP required) |
| Serum ELISA | $75-110 | $225-330 | Moderate |
| Simoa (serum) | $200-300 | $600-900 | Limited (specialized lab) |
| Lumipulse (CSF) | $150-200 | $450-600 | Moderate |
| Multiplex panel | $100-180 | $300-540 | Moderate |

Cost-Effectiveness Comparison

| Biomarker | Cost | AUC | Cost per AUC Point |
|-----------|------|-----|-------------------|
| YKL-40 (CSF) | $100 | 0.82 | $122 |
| p-Tau181 (blood) | $150 | 0.88 | $170 |
| NfL (blood) | $120 | 0.85 | $141 |
| Amyloid PET | $3,000+ | 0.90 | $3,333 |
| CSF Aβ42/40 | $250 | 0.80 | $313 |

Properties

| Property | Value |
|----------|-------|
| Category | Neuroinflammation Biomarker |
| Target | Microglial Activation |
| Sample Type | CSF, Blood (serum/plasma) |
| Diseases | Alzheimer's Disease, Parkinson's Disease, ALS, Multiple Sclerosis |
| Normal Range | CSF: 25-150 ng/mL; Serum: 20-80 ng/mL |

Molecular Biology

YKL-40 is a glycosylated hydrolase family 18 protein that lacks enzymatic activity due to mutation of the catalytic residue. It binds to chitin but does not hydrolyze it, functioning instead as a lectin-like molecule involved in:

• Cell proliferation and migration — promotes angiogenesis and tissue remodeling
• Chitin binding —虽然没有酶活性,但可以结合几丁质
• Inflammatory signaling — modulates NF-κB and MAPK pathways
• Extracellular matrix remodeling — interacts with MMPs and TIMPs

The CHI3L1 gene is located on chromosome 1q32.1 and is expressed constitutively in low levels, with dramatic upregulation during inflammation.

Role in Disease

Alzheimer's Disease

In AD, YKL-40 levels are elevated in CSF and correlate with:

• Disease progression — higher levels predict faster cognitive decline
• Amyloid burden — positive correlation with amyloid PET SUVr
• Neurodegeneration — correlates with CSF total tau and p-tau
• Microglial activation — marker of chronic neuroinflammation

Studies show YKL-40 is increased in CSF of AD patients (mean ~200 ng/mL vs ~80 ng/mL in controls) and can differentiate MCI due to AD from controls with ~80% sensitivity and specificity.

Parkinson's Disease

In PD, YKL-40 serves as a marker of:

• Disease severity — higher CSF levels correlate with UPDRS scores
• Cognitive impairment — elevated in PD-MCI and PDD
• Progression — baseline levels predict motor progression

Amyotrophic Lateral Sclerosis (ALS)

YKL-40 is elevated in ALS CSF and:

• Correlates with disease progression rate
• May differentiate ALS from other neurological conditions
• Represents ongoing neuroinflammation in the disease course

Multiple Sclerosis

In MS, YKL-40 is a marker of:

• Lesion activity — elevated in active lesions
• Disease progression — correlates with disability scores
• Treatment response — changes with disease-modifying therapy

Clinical Applications

Diagnostic Utility

YKL-40 shows promise as a complementary biomarker to established AD biomarkers:

| Comparison | Sensitivity | Specificity | AUC |
|------------|-------------|-------------|-----|
| AD vs. Controls | 75-85% | 70-80% | 0.78-0.85 |
| MCI-AD vs. MCI-stable | 70-80% | 65-75% | 0.72-0.80 |
| PD vs. Controls | 65-75% | 60-70% | 0.68-0.75 |

Prognostic Value

• AD progression — high baseline YKL-40 predicts faster MMSE decline
• PD progression — correlates with UPDRS motor score progression
• ALS progression — higher levels associated with shorter survival

Monitoring Treatment Response

YKL-40 can potentially monitor:

• Anti-inflammatory therapy efficacy
• Microglial modulation treatments
• Disease-modifying therapy effects

Detection Methods

| Method | Advantages | Limitations |
|--------|------------|-------------|
| ELISA | High sensitivity, widely available | Requires specific antibodies |
| Simoa | Ultra-sensitive, low sample volume | Limited availability |
| Multiplex | Multiple biomarkers simultaneously | Cross-reactivity concerns |

Sample Handling

• CSF: Collect via lumbar puncture, store at -80°C, avoid freeze-thaw cycles
• Serum: Collect in SST tubes, centrifuge within 1 hour, store at -80°C
• Plasma: EDTA or heparin tubes, same handling as serum

Therapeutic Implications

YKL-40 represents a therapeutic target:

• Anti-YKL-40 antibodies — being explored to reduce neuroinflammation
• CHI3L1 knockdown — reduces inflammatory responses in preclinical models
• Modulation of microglial activation — indirect therapeutic benefit

Cross-Linking

YKL-40 is linked to the following topics:

• [Neuroinflammation Pathway](/mechanisms/neuroinflammation)
• [Microglia](/cell-types/microglia)
• [Alzheimer's Disease Biomarkers](/biomarkers/alzheimers-biomarkers)
• [Parkinson's Disease Biomarkers](/biomarkers/parkinsons-biomarkers)
• [CSF Biomarkers](/biomarkers/csf-biomarkers-overview)
• [GFAP](/biomarkers/gfap)
• [TREM2](/genes/trem2)

CHI3L1 Genetics and Variants

Genetic Associations

The CHI3L1 gene (1q32.1) contains several polymorphisms associated with neurodegenerative diseases:

| SNP | Disease | Effect |
|-----|---------|--------|
| rs4959098 | Asthma, IBD | Protective |
| rs1039985 | PD risk | Increased risk |
| rs6691378 | ALS | Modified progression |
| rs1535979 | MS | Altered severity |

These genetic variants affect:

• Expression levels: eQTLs influence CHI3L1 expression
• Protein function: Altered ligand binding
• Disease susceptibility: Modified neurodegeneration risk

Gene Regulation

CHI3L1 expression is regulated by:

• Transcription factors: STAT3, AP-1, NF-κB
• Cytokines: IL-6, IL-1β, TNF-α
• Growth factors: TGF-β, PDGF
• Environmental factors: Aging, smoking, infection

Research Challenges and Future Directions

Current Limitations

Lack of specificity: Elevated in many inflammatory conditions

Biological variability: Age, sex, and comorbidities affect levels

Assay differences: Standardization needed across platforms

Limited longitudinal data: Natural history not fully characterized

Emerging Research

• YKL-40 fragments: Specific cleavage products as biomarkers
• Functional studies: Understanding CHI3L1 biological roles
• Multimodal biomarkers: Integration with imaging and other fluid markers
• Therapeutic targeting: Anti-YKL-40 strategies in development
• Population studies: Large-scale GWAS and meta-analyses

Clinical Trial Applications

YKL-40 as a biomarker in clinical trials:

| Trial Phase | Application | Utility |
|-------------|-------------|---------|
| Phase I | Safety monitoring | Inflammatory markers |
| Phase II | Dose selection | Pharmacodynamics |
| Phase III | Efficacy endpoints | Disease modification |

Biomarker Combinations

YKL-40 in biomarker panels:

| Combination | Performance | Application |
|-------------|-------------|-------------|
| YKL-40 + p-tau181 | AUC 0.80-0.86 | AD progression |
| YKL-40 + NfL) | AUC 0.75-0.82 | ALS progression |
| YKL-40 + GFAP | AUC 0.78-0.85 | Neuroinflammation |
| YKL-40 + sTREM2 | AUC 0.72-0.80 | Microglial activation |

The combination of YKL-40 with other neuroinflammation markers (GFAP, sTREM2) provides a comprehensive assessment of glial activation in neurodegenerative diseases.

Biomarker Combinations

^{<a href=#references>[1]</a>} Craig-Schapiro R, et al. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. Neurology. 2010;75(10):849-855.

^{<a href=#references>[2]</a>} Mattsson N, et al. CSF biomarkers and incipient Alzheimer disease. JAMA. 2013;309(6):555-565.

^{<a href=#references>[3]</a>} Swardfager W, et al. Chitinase-3-like protein 1: a marker of vascular injury. J Cereb Blood Flow Metab. 2019;39(11):2268-2280.

^{<a href=#references>[4]</a>} Llorens F, et al. YKL-40 in the CSF and serum of patients with Parkinson's disease. Mov Disord. 2017;32(12):1709-1717.

^{<a href=#references>[5]</a>} Steinacker P, et al. Chitinase-3-like protein 1 (CHI3L1) in ALS. Neurology. 2018;90(15):e1334-e1343.

^{<a href=#references>[6]</a>} Boddana F, et al. YKL-40 as a biomarker in multiple sclerosis. Mult Scler. 2021;27(10):1525-1535.

References

[Craig-Schapiro R, et al, YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease (2010)](https://pubmed.ncbi.nlm.nih.gov/20833908/)

[Mattsson N, et al, CSF biomarkers and incipient Alzheimer disease (2013)](https://pubmed.ncbi.nlm.nih.gov/23306194/)

[Swardfager W, et al, Chitinase-3-like protein 1: a marker of vascular injury (2019)](https://pubmed.ncbi.nlm.nih.gov/30562724/)

[Llorens F, et al, YKL-40 in the CSF and serum of patients with Parkinson's disease (2017)](https://pubmed.ncbi.nlm.nih.gov/29021269/)

[Steinacker P, et al, Chitinase-3-like protein 1 (CHI3L1) in ALS (2018)](https://pubmed.ncbi.nlm.nih.gov/29501726/)

[Boddana F, et al, YKL-40 as a biomarker in multiple sclerosis (2021)](https://pubmed.ncbi.nlm.nih.gov/33704602/)

[Persson A, et al, YKL-40 in cerebrospinal fluid and its relationship to neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/32895751/)

[Olsson B, et al, Microglial markers are elevated in the CSF of Alzheimer's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31659342/)

See Also

• [Alzheimer's Disease Biomarkers](/biomarkers/alzheimers-biomarkers)
• [Parkinson's Disease Biomarkers](/biomarkers/parkinsons-biomarkers)
• [CSF Biomarkers Overview](/biomarkers/csf-biomarkers-overview)
• [GFAP](/biomarkers/gfap)
• [TDP-43](/biomarkers/tdp-43)
• [Neuroinflammation Pathway](/mechanisms/neuroinflammation)

External Links

• [CHI3L1 Gene - NCBI](https://www.ncbi.nlm.nih.gov/gene/1116)
• [YKL-40 ELISA - Fujirebio](https://www.fujirebio.com)
• [Alzheimer's Disease Neuroimaging Initiative (ADNI)](https://adni.loni.usc.edu)

Pathway Diagram

The following diagram shows the key molecular relationships involving YKL-40 (CHI3L1) - Biomarker discovered through SciDEX knowledge graph analysis: